Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling von She, Qing-Bai, Chandarlapaty, Sarat, Ye, Qing, Lobo, Jose, Haskell, Kathleen M, Leander, Karen R, DeFeo-Jones, Deborah, Huber, Hans E, Rosen, Neal

Volltext

Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors von Lindsley, Craig W., Zhao, Zhijian, Leister, William H., Robinson, Ronald G., Barnett, Stanley F., Defeo-Jones, Deborah, Jones, Raymond E., Hartman, George D., Huff, Joel R., Huber, Hans E., Duggan, Mark E.

Volltext

Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors von Barnett, Stanley F, Defeo-Jones, Deborah, Fu, Sheng, Hancock, Paula J, Haskell, Kathleen M, Jones, Raymond E, Kahana, Jason A, Kral, Astrid M, Leander, Karen, Lee, Ling L, Malinowski, John, McAvoy, Elizabeth M, Nahas, Debbie D, Robinson, Ronald G, Huber, Hans E

Volltext

Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members von DeFeo-Jones, Deborah, Barnett, Stanley F, Fu, Sheng, Hancock, Paula J, Haskell, Kathleen M, Leander, Karen R, McAvoy, Elizabeth, Robinson, Ronald G, Duggan, Mark E, Lindsley, Craig W, Zhao, Zhijian, Huber, Hans E, Jones, Raymond E

Volltext

Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors von Zhao, Zhijian, Leister, William H., Robinson, Ronald G., Barnett, Stanley F., Defeo-Jones, Deborah, Jones, Raymond E., Hartman, George D., Huff, Joel R., Huber, Hans E., Duggan, Mark E., Lindsley, Craig W.

Volltext

An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo von Cherrin, Craig, Haskell, Kathleen, Howell, Bonnie, Jones, Raymond, Leander, Karen, Robinson, Ronald, Watkins, Aubrey, Bilodeau, Mark, Hoffman, Jacob, Sanderson, Philip, Hartman, George, Mahan, Elizabeth, Prueksaritanont, Thomayant, Jiang, Guoqiang, She, Qing-Bai, Rosen, Neal, Sepp-Lorenzino, Laura, Defeo-Jones, Deborah, Huber, Hans E.

Volltext

A peptide–doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo von DeFeo-Jones, Deborah, Garsky, Victor M., Wong, Bradley K., Feng, Dong-Mei, Bolyar, Trina, Haskell, Kathleen, Kiefer, David M., Leander, Karen, McAvoy, Elizabeth, Lumma, Patricia, Wai, Jenny, Senderak, Edith T., Motzel, Sherri L., Keenan, Kevin, Zwieten, Matthew Van, Lin, Jiunn H., Freidinger, Roger, Huff, Joel, Oliff, Allen, Jones, Raymond E.

Volltext

Synthesis and biological evaluation of unnatural canthine alkaloids von Lindsley, Craig W., Bogusky, Michael J., Leister, William H., McClain, Ray T., Robinson, Ronald G., Barnett, Stanley F., Defeo-Jones, Deborah, Ross, Charles W., Hartman, George D.

Volltext

Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice von Arredouani, Mohamed S., Tseng-Rogenski, Stephanie S., Hollenbeck, Brent K., Escara-Wilke, June, Leander, Karen R., Defeo-Jones, Deborah, Hwang, Clara, Sanda, Martin G.

Volltext

Tumors secreting human TNF/cachectin induce cachexia in mice von Oliff, Allen, Defeo-Jones, Deborah, Boyer, Mark, Martinez, Douglas, Kiefer, David, Vuocolo, Gerald, Wolfe, Abigail, Socher, Susan H.

Volltext

A Prostate-specific Antigen (PSA)-activated Vinblastine Prodrug Selectively Kills PSA-secreting Cells in Vivo von DeFeo-Jones, Deborah, Brady, Stephen F, Feng, Dong-Mei, Wong, Bradly K, Bolyar, Trina, Haskell, Kathleen, Kiefer, David M, Leander, Karen, McAvoy, Elizabeth, Lumma, Patricia, Pawluczyk, Joseph M, Wai, Jenny, Motzel, Sherri L, Keenan, Kevin, Van Zwieten, Matthew, Lin, Jiunn H, Garsky, Victor M, Freidinger, Roger, Oliff, Allen, Jones, Raymond E

Volltext

Allosteric inhibitors of Akt1 and Akt2: A naphthyridinone with efficacy in an A2780 tumor xenograft model von Bilodeau, Mark T., Balitza, Adrienne E., Hoffman, Jacob M., Manley, Peter J., Barnett, Stanley F., Defeo-Jones, Deborah, Haskell, Kathleen, Jones, Raymond E., Leander, Karen, Robinson, Ronald G., Smith, Anthony M., Huber, Hans E., Hartman, George D.

Volltext

Allosteric inhibitors of Akt1 and Akt2: Discovery of [1,2,4]triazolo[3,4-f][1,6]naphthyridines with potent and balanced activity von Li, Yiwei, Liang, Jun, Siu, Tony, Hu, Essa, Rossi, Michael A., Barnett, Stanley F., Defeo-Jones, Deborah, Jones, Raymond E., Robinson, Ronald G., Leander, Karen, Huber, Hans E., Mittal, Sachin, Cosford, Nicholas, Prasit, Peppi

Volltext

Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity von Zhao, Zhijian, Robinson, Ronald G., Barnett, Stanley F., Defeo-Jones, Deborah, Jones, Raymond E., Hartman, George D., Huber, Hans E., Duggan, Mark E., Lindsley, Craig W.

Volltext

Rapid assembly of diverse and potent allosteric Akt inhibitors von Wu, Zhicai, Robinson, Ronald G., Fu, Sheng, Barnett, Stanley F., Defeo-Jones, Deborah, Jones, Raymond E., Kral, Astrid M., Huber, Hans E., Kohl, Nancy E., Hartman, George D., Bilodeau, Mark T.

Volltext

The design and synthesis of potent and cell-active allosteric dual Akt 1 and 2 inhibitors devoid of hERG activity von Siu, Tony, Li, Yiwei, Nagasawa, Johnny, Liang, Jun, Tehrani, Lida, Chua, Peter, Jones, Raymond E., Defeo-Jones, Deborah, Barnett, Stanley F., Robinson, Ronald G.

Volltext

Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors von Hartnett, John C., Barnett, Stanley F., Bilodeau, Mark T., Defeo-Jones, Deborah, Hartman, George D., Huber, Hans E., Jones, Raymond E., Kral, Astrid M., Robinson, Ronald G., Wu, Zhicai

Volltext

The Synthesis of a Prodrug of Doxorubicin Designed to Provide Reduced Systemic Toxicity and Greater Target Efficacy von Garsky, Victor M, Lumma, Patricia K, Feng, Dong-Mei, Wai, Jenny, Ramjit, Harri G, Sardana, Mohinder K, Oliff, Allen, Jones, Raymond E, DeFeo-Jones, Deborah, Freidinger, Roger M

Volltext

Discovery of potent and cell-active allosteric dual Akt 1 and 2 inhibitors von Siu, Tony, Liang, Jun, Arruda, Jeannie, Li, Yiwei, Jones, Raymond E., Defeo-Jones, Deborah, Barnett, Stanley F., Robinson, Ronald G.

Volltext

Development of Pyridopyrimidines as Potent Akt1/2 Inhibitors von Wu, Zhicai, Hartnett, John C., Neilson, Lou Anne, Robinson, Ronald G., Fu, Sheng, Barnett, Stanley F., Defeo-Jones, Deborah, Jones, Raymond E., Kral, Astrid M., Huber, Hans E., Hartman, George D., Bilodeau, Mark T.

Volltext